Results 101 to 110 of about 571 (112)

Safety and tolerability of spesolimab in patients with ulcerative colitis

Expert Opinion on Drug Safety, 2023
Savion Gropper, Thomas Haeufel, Jochen Klaus   +2 more
exaly  

Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial

Lancet, The, 2023
Thomas Haeufel, Christian Thoma
exaly  

Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis

Journal of Allergy and Clinical Immunology, 2022
Patrick Baum, Sudha Visvanathan, Sandra Garcet   +2 more
exaly  

Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study

Dermatology and Therapy, 2021
Ulrich Mrowietz, A D Burden, KRISTIAN Reich   +2 more
exaly  

Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study

Journal of the American Academy of Dermatology, 2023
Boni E Elewski, Christian Thoma
exaly  

Spesolimab: A Review of the First IL-36 Blocker Approved for Generalized Pustular Psoriasis

Annals of Pharmacotherapy
Gaurav N Pathak, Jimmy Dhillon, Prachi Parikh   +2 more
exaly  

Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization of Flare Treatment in EFFISAYIL 1

Journal of Investigative Dermatology
German Leparc, Christian Thoma
exaly  

Generalized pustular psoriasis patient with a heterozygous hypomorphic MPO variant refractory to intravenous spesolimab

Journal of Dermatology
Youichi Ogawa, Takuya Takeichi, Takashi Okamoto   +2 more
exaly